Results 191 to 200 of about 542,843 (395)
Nonlinear creep constitutive model of rock under water and force conditions. [PDF]
Peng GC, Zhu ZG, An JJ, Xu HH, Zhu T.
europepmc +1 more source
Analysis of some basic creep tests on concrete and their implications for modeling
Jean‐Michel Torrenti, Robert Le Roy
openalex +2 more sources
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon +13 more
wiley +1 more source
Alternative to MSCR Test: A Novel Rheological Method for Evaluating Asphalt Mastic Performance at High Temperatures. [PDF]
Trifunović S, Büchner J, Wistuba MP.
europepmc +1 more source
Creep and morphological evaluation of polypropylene waste modified asphalt for pavement applications
Hassan Suleiman Otuoze +5 more
openalex +2 more sources
Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li +10 more
wiley +1 more source
Fluid Creep as an Independent Predictor of Fluid Overload and Mortality in Critically Ill Patients: A Cohort Study. [PDF]
Briassoulis G +4 more
europepmc +1 more source
Large strain consolidation model for very soft soils with prefabricated horizontal drains considering nonlinear compression and creep [PDF]
Penglin Li +3 more
openalex +1 more source
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source

